Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.32 CHF | +1.97% | +4.94% | +8.78% |
May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
Sales 2024 * | 48.96B 44.35B | Sales 2025 * | 50.79B 46.01B | Capitalization | 208B 188B |
---|---|---|---|---|---|
Net income 2024 * | 10.5B 9.51B | Net income 2025 * | 12.07B 10.93B | EV / Sales 2024 * | 4.51 x |
Net Debt 2024 * | 12.88B 11.66B | Net Debt 2025 * | 11.28B 10.22B | EV / Sales 2025 * | 4.31 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
17.3
x | Employees | 76,057 |
Yield 2024 * |
3.55% | Yield 2025 * |
3.68% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | +1.97% | ||
1 week | +4.94% | ||
Current month | +3.67% | ||
1 month | +7.19% | ||
3 months | +5.29% | ||
6 months | +10.09% | ||
Current year | +8.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | ||
5.57% | 0 M€ | +7.69% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 92.32 | +1.97% | 3,233,804 |
24-05-08 | 90.54 | +0.85% | 2,553,649 |
24-05-07 | 89.78 | +1.91% | 2,442,038 |
24-05-06 | 88.1 | +0.15% | 1,420,503 |
24-05-03 | 87.97 | -1.01% | 2,231,035 |
Delayed Quote Swiss Exchange, May 10, 2024 at 11:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 208B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock